New York Life Investment Management LLC cut its stake in Arcus Biosciences, Inc. (NYSE:RCUS – Free Report) by 13.6% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 19,520 shares of the company’s stock after selling 3,075 shares during the period. New York Life Investment Management LLC’s holdings in Arcus Biosciences were worth $350,000 as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors also recently bought and sold shares of the company. Alpha DNA Investment Management LLC acquired a new stake in Arcus Biosciences during the 3rd quarter valued at approximately $462,000. Barclays PLC lifted its stake in Arcus Biosciences by 183.4% during the 3rd quarter. Barclays PLC now owns 470,776 shares of the company’s stock valued at $8,451,000 after acquiring an additional 304,683 shares during the period. Fox Run Management L.L.C. acquired a new position in shares of Arcus Biosciences in the 3rd quarter valued at $356,000. Arizona State Retirement System boosted its holdings in Arcus Biosciences by 10.0% during the third quarter. Arizona State Retirement System now owns 13,530 shares of the company’s stock worth $243,000 after buying an additional 1,226 shares in the last quarter. Finally, Illinois Municipal Retirement Fund purchased a new stake in Arcus Biosciences during the third quarter worth $494,000. 74.67% of the stock is currently owned by institutional investors and hedge funds.
Arcus Biosciences Price Performance
Shares of RCUS stock opened at $16.47 on Tuesday. The firm has a market cap of $1.23 billion, a PE ratio of -4.12 and a beta of 0.78. The company has a 50-day moving average of $16.91 and a two-hundred day moving average of $17.37. Arcus Biosciences, Inc. has a 1-year low of $12.95 and a 1-year high of $25.47.
Insiders Place Their Bets
Analysts Set New Price Targets
RCUS has been the topic of a number of recent analyst reports. Wedbush lowered their price target on shares of Arcus Biosciences from $36.00 to $30.00 and set an “outperform” rating on the stock in a report on Tuesday, January 30th. Mizuho reduced their price objective on shares of Arcus Biosciences from $51.00 to $42.00 and set a “buy” rating for the company in a research report on Tuesday, January 30th. Cantor Fitzgerald reduced their price objective on shares of Arcus Biosciences from $46.00 to $36.00 and set an “overweight” rating for the company in a research report on Wednesday, November 8th. Finally, Morgan Stanley reduced their price objective on shares of Arcus Biosciences from $38.00 to $35.00 and set an “overweight” rating for the company in a research report on Monday, November 13th. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Arcus Biosciences presently has a consensus rating of “Moderate Buy” and a consensus target price of $41.25.
Arcus Biosciences Company Profile
Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT investigational monoclonal antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.
- Five stocks we like better than Arcus Biosciences
- Investing in the High PE Growth Stocks
- 3 attractive stocks that insiders are buying
- Industrial Products Stocks Investing
- Alpha and Omega Semiconductor ready to bounce, DOJ cloud lifts
- How to Invest in Tech Stocks and Top Tech Stocks to Consider
- Wendy’s vs Shake Shack: Out with the new, in with the old?
Receive News & Ratings for Arcus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.